Spots Global Cancer Trial Database for Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Official Title: An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
Study ID: NCT03275103
Conditions
Study Description
Brief Summary: This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic Hospital - Arizona, Scottsdale, Arizona, United States
City of Hope, Duarte, California, United States
University of California San Francisco, San Francisco, California, United States
University of Colorado Denver, Aurora, Colorado, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mount Sinai Hospital, New York, New York, United States
Memorial Sloan Kettering, New York, New York, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Alfred Hospital, Melbourne, Victoria, Australia
Peter MacCallum Cancer Center, North Melbourne, Victoria, Australia
University of Calgary, Calgary, Alberta, Canada
Princess Margaret Cancer Center, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, , Spain
Contact Details
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
